Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept-based Immunosuppression in Renal Transplant
NCT02137239Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Primary completion
- May 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of belatacept in kidney transplant rejection, sponsored by Bristol Myers Squibb. Started Dec 2015; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02137239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137239.